Related Experiment Video
Updated: May 13, 2025
04:29
Vagus Nerve Stimulation As an Adjunctive Neurostimulation Tool in Treatment-resistant Depression
Published on: January 7, 2019
28.1K
Yoga for Depressive Disorder: A Systematic Review and Meta-Analysis
Alina Moosburner1,2, Holger Cramer1,2, Mirela Bilc1,2
1Institute of General Practice and Interprofessional Care, University Hospital Tübingen, Tübingen, Germany.
Depression and Anxiety
|April 14, 2025
Summary
Yoga effectively reduces depression severity compared to passive control and improves remission rates against active and passive controls. Despite inconsistent evidence quality, yoga offers a favorable risk-benefit profile for treating depression, especially major depressive disorder (MDD).
Area of Science:
- Integrative medicine and mental health research.
- Clinical psychology and psychiatry.
- Evidence-based complementary therapies for mood disorders.
Background:
- Rising global prevalence of depression.
- Limitations of conventional depression therapies, including treatment gaps and non-response rates.
- Need for alternative and complementary treatment options.
Purpose of the Study:
- To systematically review and evaluate the evidence for yoga's efficacy in treating depressive disorders.
- To assess yoga's impact on depression severity, remission rates, quality of life, and safety.
- To provide an updated analysis of yoga as a therapeutic intervention for depression.
Main Methods:
- Systematic literature search across multiple databases (PubMed/Medline, Cochrane Library, Scopus, PsycINFO, BASE).
- Inclusion of randomized controlled trials (RCTs) in participants with depressive disorders.
- Meta-analysis of depression severity and remission rates, with separate analyses for active and passive control groups and subgroups (major depressive disorder, mixed samples); risk of bias and quality of evidence (GRADE) assessment.
Main Results:
- Yoga demonstrated a significant short-term reduction in depression severity versus passive control (SMD = -0.43).
- Yoga significantly increased remission rates compared to both passive (OR = 3.20) and active controls (OR = 2.04).
- No significant differences in safety outcomes were found compared to control groups; evidence quality ranged from moderate to very low.
Conclusions:
- Yoga is an effective therapy for reducing depression severity and improving remission rates in patients with depressive disorders.
- The intervention shows a positive risk-benefit ratio, supporting its consideration as a treatment option, particularly for major depressive disorder (MDD).
- Further research with consistent outcome reporting is needed to strengthen the evidence base, especially regarding quality of life.
Related Concept Videos
01:18Depression: Overview
197
Depression is a prevalent mental illness marked by persistent sadness and lack of interest in previously enjoyable activities. It can take several forms, including major depression, persistent depressive disorder, and bipolar I and II disorders. Symptoms range from emotional changes like chronic worry to physical changes like sleep disturbances and suicidal thoughts. From a neurobiological perspective, depression is believed to be triggered by abnormalities in the brain's prefrontal cortex,...
197
01:27Depressive Disorders: MDD and Dysthymia
17
Depressive disorders are a group of mental health conditions characterized by pervasive feelings of sadness, diminished pleasure in life, and a significant impact on daily functioning. These conditions are most prevalent in individuals during their 30s and affect women at twice the rate of men. Contrary to popular belief, younger individuals are generally more susceptible to these disorders than older adults. Two key types of depressive disorders include Major Depressive Disorder (MDD) and...
17
01:27Depressive Disorders: Etiology
19
Depressive disorders result from a complex interplay of biological, psychological, and sociocultural factors, each contributing uniquely to the development and persistence of the condition. Understanding these factors provides critical insight into the multifaceted nature of depression.
Biological Factors in Depression
Biological predispositions significantly influence the risk of developing depressive disorders. Genetic studies highlight the role of variations in the serotonin transporter...
Biological Factors in Depression
Biological predispositions significantly influence the risk of developing depressive disorders. Genetic studies highlight the role of variations in the serotonin transporter...
19
01:23Antidepressant Drugs: MAOIs and Other Agents
164
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
164
01:25Stress Prevention and Stress Management Techniques III
23
Regular exercise and meditation serve as essential tools in managing stress and promoting physical and mental well-being.
The Role of Exercise in Stress Management
Regular physical activity is essential for reducing stress and promoting cardiovascular health. Exercise strengthens the heart, enhances blood flow, keeps blood vessels flexible, and helps lower blood pressure, all of which reduce the body's stress response. Research shows that adults who exercise regularly have nearly half the...
The Role of Exercise in Stress Management
Regular physical activity is essential for reducing stress and promoting cardiovascular health. Exercise strengthens the heart, enhances blood flow, keeps blood vessels flexible, and helps lower blood pressure, all of which reduce the body's stress response. Research shows that adults who exercise regularly have nearly half the...
23
01:28Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs
235
Tricyclic Antidepressants (TCAs), including Desipramine (Norpramin), Imipramine (Tofranil), Clomipramine (Anafranil), and Amitriptyline (Elavil), inhibit serotonin and norepinephrine reuptake and also block other receptors. They are used for depression, pain conditions, and insomnia. Common adverse effects include anticholinergic effects, sedation, orthostatic hypotension, and weight gain. They have a narrow therapeutic window and so require plasma-level monitoring. Abrupt discontinuation can...
235